<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is a common <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo> and it is associated with systemic <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Until recently, <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> (VKA) such as <z:chebi fb="8" ids="10033">warfarin</z:chebi> were the only available oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy for prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> in AF </plain></SENT>
<SENT sid="2" pm="."><plain>Limitations of VKA therapy have prompted researchers to search for novel <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> drugs, which do not necessitate coagulation monitoring due to their more predictable pharmacokinetic profile </plain></SENT>
<SENT sid="3" pm="."><plain>Large-scale phase III trials have been completed for some of these drugs and 'U.S </plain></SENT>
<SENT sid="4" pm="."><plain>Food and Drug Administration (FDA)' approved dabigatran and rivaroxaban for prevention of <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> in non-valvular AF patients </plain></SENT>
<SENT sid="5" pm="."><plain>In this review, we will first focus on pharmacodynamic and pharmacokinetic profiles of these medications and then try to overview clinical trial results </plain></SENT>
<SENT sid="6" pm="."><plain>We will also try to mention the current controversies regarding the clinical application of these drugs </plain></SENT>
</text></document>